Sign In
Buy KTRA
$0.215
+0 (+0%)
At Close: Jan 16, 2025
Aegis Capital gives Kintara Therapeutics a ‘Buy' rating
09:29am, Friday, 01'st Oct 2021
Kintara Therapeutics Inc, an oncology-focused, clinical-stage biopharmaceutical company received a ‘Buy' rating from Aegis Capital. The analysts noted the biotech firm, which is developing VAL-0
Kintara Therapeutics: Q4 Earnings Insights
07:16am, Thursday, 30'th Sep 2021
Kintara Therapeutics(NASDAQ:KTRA) stock fell by 5.89% on Wednesday after the company reported its Q4 earnings results on Tuesday, September 28, 2021 at 08:00 AM. Here's what investors need to know abo
Kintara heads into new fiscal year with strengthened balance sheet
09:53am, Wednesday, 29'th Sep 2021
Kintara Inc, a biopharmaceutical company focused on the development of new solid tumor cancer therapies, reports that it closed its fiscal year on June 30 with cash and cash equivalents of about $10.5
Kintara Therapeutics Announces Fiscal Year 2021 Financial Results and Provides Corporate Update
08:00am, Wednesday, 29'th Sep 2021
SAN DIEGO, Sept. 29, 2021 /PRNewswire/ -- https://www.kintara.com/ (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer therap
Kintara Announces Closing of $15.0 million Offering Priced at a Premium to Market
01:33pm, Tuesday, 28'th Sep 2021
SAN DIEGO, Sept. 28, 2021 /PRNewswire/ -- Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company developing novel cancer therapies for patients who are fai
Kintara announces $15M common stock and warrants offering priced at premium to market
09:02am, Friday, 24'th Sep 2021
Kintara Therapeutics Inc has entered into securities purchase agreements with certain healthcare-focused institutional investors to raise about $15 million in gross proceeds. The company said it int
Kintara Announces $15.0 million Offering of Common Stock and Warrants Priced at a Premium to Market
08:00am, Friday, 24'th Sep 2021
SAN DIEGO, Sept. 24, 2021 /PRNewswire/ -- Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company developing novel cancer therapies for patients who are fa
Kintara Therapeutics is developing innovative cancer therapies for rare, unmet medical needs
11:38am, Friday, 10'th Sep 2021
Two Phase 3-ready therapeutics Well capitalized to achieve clinical milestones Multiple US/EU Orphan Drug and Fast Track designations What Kintara Therapeutics does: Kintara Therapeutics, Inc (NASDAQ
Kintara Therapeutics Inc has announced that the VAL-083 treatment arm in the Global Coalition for Adaptive Research (GCAR) registrational Phase 2/3 clinical trial for glioblastoma multiforme (GBM) has
Kintara Therapeutics Provides Positive Site Activation Update on GCAR Phase 2/3 Clinical Trial for Glioblastoma
08:00am, Tuesday, 17'th Aug 2021
SAN DIEGO, Aug. 17, 2021 /PRNewswire/ -- Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer thera
Kintara Therapeutics is developing innovative cancer therapies for rare, unmet medical needs
09:43pm, Tuesday, 06'th Jul 2021
Two Phase 3-ready therapeutics Well capitalized to achieve clinical milestones Multiple US/EU Orphan Drug and Fast Track designations What Kintara Therapeutics does: Kintara Therapeutics, Inc (NASDAQ
Kintara Therapeutics Shows Encouraging Safety, Efficacy Data From Brain Cancer Study With VAL-083
01:36pm, Thursday, 01'st Jul 2021
Kintara Therapeutics Inc (NASDAQ: KTRA) has announced topline data from Phase 2 study of its lead compound VAL-083, conducted at the MD Anderson Cancer Center. The Phase 2 trial is a two-arm, bioma
KTRA Stock Price Increases Over 25% Pre-Market: Why It Happened
08:29am, Thursday, 01'st Jul 2021
The stock price of Kintara Therapeutics Inc (NASDAQ: KTRA) increased by over 25% pre-market. This is why it happened.
Kintara Reports Topline Results From Phase 2 Clinical Trial of VAL-083 for Recurrent GBM
08:00am, Thursday, 01'st Jul 2021
SAN DIEGO, July 1, 2021 /PRNewswire/ -- Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company developing novel cancer therapies for patients who are fai
7 Stocks to Buy Under $5 for Big Gains
04:58pm, Wednesday, 30'th Jun 2021
If you really want to take a walk on the wild side, there are several stocks to buy under $5. But be prepared for unpredictability.
